Biogen Subpoenaed by Feds Over Pricing, Rebates

Feb 03, 2017

Boston Biz Journal

Biogen announced it had received a subpoena from the federal government related to government price reporting and rebate payments for top multiple sclerosis drugs.

The company said it had received a subpoena on Dec. 5 seeking information about "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy.

Biogen says it is cooperating with the federal government on the investigation.

Read the Boston Biz Journal coverage 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments